|1.||Mason, Anne B: 1 article (02/2007)|
|2.||Pham, Edward A: 1 article (02/2007)|
|3.||Lao, Bert J: 1 article (02/2007)|
|4.||Kamei, Daniel T: 1 article (02/2007)|
|5.||Mashayekhi, Foad: 1 article (02/2007)|
|6.||Tsai, Wen-Lin P: 1 article (02/2007)|
03/01/1994 - "This study also characterized the dose-response effect of Tf-CRM107 on tumor growth and tumor weight on Day 30. "
03/01/1994 - "With intratumoral administration, the effect of Tf-CRM107 was tumor-specific and in some animals curative. "
03/01/1994 - "All three doses of Tf-CRM107 significantly inhibited tumor growth by Day 14 (p < 0.01) and at Day 30 (p < 0.05), with a significant dose-response relationship. "
03/01/1994 - "Treatment with equimolar doses of the unconjugated targeted protein toxin components CRM107, 454A12, or rRA caused significant U251 MG tumor growth inhibition, but the effects were less potent than the antitumor effects of the conjugates. "
03/01/1994 - "With Tf-CRM107 administration, tumor regression of greater than 95% occurred by Day 14 (p < 0.01) and tumors did not recur by Day 30. "
|4.||Brain Neoplasms (Brain Tumor)
|2.||Transferrin (beta 2 Transferrin)
|4.||CRM45 fragment of diphtheria toxin